Revenue
213 thousand Unit12
2019 Q4 · Unit12
Fundies. English
MARKER THERAPEUTICS, INC.
EDGAR143 filing records in this dataset, filed from 1999-11-15 to 2026-10-19. Reported financial figures are available; chart coverage varies by period.
Latest quarter
Operating margin
-2,515.1%
2019 Q4 · %
Operating cash flow
-4.56 million Unit12
2019 Q4 · Unit12
Free cash flow
-4.57 million Unit12
2019 Q4 · Unit12
- Cash and cash equivalents
- 11.3 million Unit_Standard_USD_ES0uZbXt7U2xLzIkNkzBpw Source
Exact value
11331023 Unit_Standard_USD_ES0uZbXt7U2xLzIkNkzBpw
- Long-term debt including current maturities
- Not available
- Shares outstanding
- 16.7 million Unit_Standard_shares_kmLnHAyFmk6GlW8h6NzT2Q Source
Exact value
16700000 Unit_Standard_shares_kmLnHAyFmk6GlW8h6NzT2Q
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-10-19.
Financial data available through: 2025-12-31.
Coverage by financial measure
- Revenue: 2 of 11 periods available· newest 2021-12-31
- Operating income: 2 of 11 periods available· newest 2025-12-31
- Net income: 2 of 11 periods available· newest 2025-12-31
- Operating cash flow: 2 of 11 periods available· newest 2025-12-31
- Capital expenditure: 2 of 11 periods available· newest 2019-12-31
- Total assets: Multiple units; comparison withheld· newest 2025-12-31
- Total liabilities: Multiple units; comparison withheld· newest 2025-12-31
- Current assets: Multiple units; comparison withheld· newest 2025-12-31
- Current liabilities: Multiple units; comparison withheld· newest 2025-12-31
- Cash and cash equivalents: Multiple units; comparison withheld· newest 2025-12-31
- long term debt: No compatible figures in this window
- Shares outstanding: Multiple units; comparison withheld· newest 2025-12-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Net income
−Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A 1.43 millionPrior period
−Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A 10.73 million
–
Current period
−Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A 12.16 million
–
Exact inputs and evidence
-12163620 − -10731315 = -1432305 Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A
-10731315 Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-12163620 Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A 1.1 millionPrior period
−Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A 10.91 million
–
Current period
−Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A 12.01 million
–
Exact inputs and evidence
-12014081 − -10910324 = -1103757 Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A
-10910324 Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-12014081 Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Revenue, Capital expenditure.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
2021 2021-01-01 – 2021-12-31
- Revenue Unit_Standard_USD_49at0_SenU-6neGg-JmKPQ 0
- Operating costs Derived Unavailable An input is unavailable.
- Operating income Unavailable An input is unavailable.
- Tax, interest and other Derived Unavailable An input is unavailable.
- Net income Unavailable An input is unavailable.
Cash
- Operating cash flow Unavailable An input is unavailable.
- Capital expenditure Unavailable An input is unavailable.
- Free cash flow Derived Unavailable An input is unavailable.
Share of revenue by period
- Net income
- Tax, interest and other
- Operating costs
- 2020 Not shown: operating income or net income is not reported.
- 2021 Not shown: operating income or net income is not reported.
Values and sources
| Period | Revenue | Operating costs | Operating income | Tax, interest and other | Net income | Free cash flow | Source |
|---|---|---|---|---|---|---|---|
| 2020 2020-01-01 – 2020-12-31 | 500000 | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Source
|
| 2021 2021-01-01 – 2021-12-31 | 0 | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Source
|
Amounts are exact, in Unit_Standard_USD_49at0_SenU-6neGg-JmKPQ.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
Unit_Standard_USD_49at0_SenU-6neGg-JmKPQ 0 2021
Values and sources
| Period | Series | Value(Unit_Standard_USD_49at0_SenU-6neGg-JmKPQ) | Source evidence |
|---|---|---|---|
| 2020 | Revenue | 500000 |
|
| 2021 | Revenue | 0 |
|
Revenue growth
Change in revenue from the same financial period one year earlier.
-100% 2021
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2020 | Year over year | No prior comparable period |
|
| 2021 | Year over year | -100% |
|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Not enough comparable data to show this history.
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2020-12-31 | Operating margin | Not reported |
|
| 2021-12-31 | Operating margin | Not reported |
|
| 2020-12-31 | Net margin | Not reported |
|
| 2021-12-31 | Net margin | Not reported |
|
| 2020 | Free cash flow margin | Not reported |
|
| 2021 | Free cash flow margin | Not reported |
|
Operating cash flow
Cash generated by the company’s normal business operations.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value(Unit_Standard_USD_49at0_SenU-6neGg-JmKPQ) | Source evidence |
|---|---|---|---|
| 2020 | Operating cash flow | Not reported | No source recorded |
| 2021 | Operating cash flow | Not reported | No source recorded |
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2020 | Free cash flow | Unavailable | No source recorded |
| 2021 | Free cash flow | Unavailable | No source recorded |
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2020-12-31 | Liabilities / assets | Not reported | No source recorded |
| 2021-12-31 | Liabilities / assets | Not reported | No source recorded |
Current assets to current liabilities
Current assets divided by current liabilities.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2020-12-31 | Current assets / current liabilities | Not reported | No source recorded |
| 2021-12-31 | Current assets / current liabilities | Not reported | No source recorded |
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2024 2024-01-01 – 2024-12-31 | −Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A 10.73 million Exact valueExact value: -10731315 Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A 2024-01-01 – 2024-12-31: -10731315 Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A Inspect Net Income Open source Share or citeThe citation records this snapshot. The page link may show a newer release later. | −Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A 10.91 million Exact valueExact value: -10910324 Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A 2024-01-01 – 2024-12-31: -10910324 Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A Inspect Operating Cash Flow Open source Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2025 2025-01-01 – 2025-12-31 | −Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A 12.16 million Exact valueExact value: -12163620 Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A 2025-01-01 – 2025-12-31: -12163620 Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A Inspect Net Income Open source Share or citeThe citation records this snapshot. The page link may show a newer release later. | −Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A 12.01 million Exact valueExact value: -12014081 Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A 2025-01-01 – 2025-12-31: -12014081 Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A Inspect Operating Cash Flow Open source Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
143 filings · 4,024 latest values · 4,024 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001094038, 1094038, MRKR, TPIV, edgar:1094038, tpiv
Also known as EDUVERSE COM, GENEMAX CORP, MARKER THERAPEUTICS, INC., MARKER THERAPEUTICS, INC., Marker Therapeutics, Inc., TAPIMMUNE INC, TAPIMMUNE INC.